WALDENCAST A DL -,0001 Aktie

Waldencast has completed the sale of its dermatology and aesthetics business Obagi Medical to Bridgepoint; the transaction is worth up to $460 million and is subject to customary adjustments. The sale proceeds were used to fully repay all outstanding senior credit facilities. Waldencast will now focus on the Milk Makeup brand; founders Michel Brousset and Hind Sebti and CFO Manuel Manfredi are leaving the company to run Obagi together with Bridgepoint, while Felipe Dutra will assume the duties of CEO and CFO. » Plus sur de.investing.com

Waldencast set its ordinary general meeting for fiscal 2025 for 14 January 2026 in London; the record date for participation and voting is 9 December 2025. Lindsay Pattison and Zack Werner have announced their resignations; the board will be reclassified into three classes and shareholders will vote on the re-election of the class-III directors. The company reported delayed revenue figures for Q2 and Q3 that missed expectations, with Milk Makeup showing a 20% revenue decline; Canaccord Genuity and Jefferies consequently lowered their price targets but each kept a "Buy" rating. » Plus sur de.investing.com

Waldencast received FDA approval for the hyaluronic filler Obagi® saypha® MagIQ™, which is to be launched in the US in 2026. The company expects this to raise the market potential to around $4.2 billion by 2029; Waldencast reports a gross margin of 70% and most recently 25.55% revenue growth. Waldencast also acquired Novaestiq and the US rights to the Saypha line, but postponed its Q2 figures and cut 2025 guidance; analysts responded with target adjustments and mixed ratings. » Plus sur de.investing.com